The Saudi Food and Drug Authority (SFDA) announced on 1 September 2025 that it had approved a biotechnology-based in vitro diagnostic test designed to aid the early detection of Alzheimer's disease by measuring a specific biomarker in blood plasma.
The announcement reflects the expanding role of less-invasive biomarker testing in neurodegenerative-disease pathways. The test is an aid within a wider clinical assessment; laboratory use must continue to follow the authorized intended use, validated instruments and reagents, documented sample handling, quality-control procedures, and qualified clinical interpretation.
Why this matters for laboratories
- Earlier investigation: blood-based biomarkers may help clinicians identify patients who need further assessment.
- Workflow readiness: pre-analytical quality, traceability, calibration, and internal quality control remain essential.
- Responsible adoption: laboratories should verify local authorization, intended-use limitations, and staff competency before implementation.
Source: Saudi Food and Drug Authority.
العربية
English